Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Aprea Therapeutics ( (APRE) ) has issued an update.
On January 9, 2026, Aprea Therapeutics updated its corporate presentation, outlining a development roadmap through 2026 that highlights multiple DDR-focused drug candidates and clinical milestones in early-stage oncology trials. The company detailed progress on its ATR inhibitor ATRN-119, for which further monotherapy enrollment has been paused in favor of exploring combination strategies, and on its WEE1 inhibitor APR-1051, which is being advanced toward clinical proof-of-concept as a potentially safer alternative in a target class historically limited by toxicity. The refreshed deck emphasizes Aprea’s strategy to capitalize on synthetic lethality as a validated cancer-killing approach, positioning the firm to benefit from rising global cancer incidence and sustained demand for targeted therapies, while showcasing an experienced management team and board with deep expertise in oncology drug development and commercialization.
The most recent analyst rating on (APRE) stock is a Hold with a $0.89 price target. To see the full list of analyst forecasts on Aprea Therapeutics stock, see the APRE Stock Forecast page.
Spark’s Take on APRE Stock
According to Spark, TipRanks’ AI Analyst, APRE is a Neutral.
The score is primarily constrained by weak financial performance (persistent losses and cash burn) and bearish technicals (price below key moving averages with negative MACD). Valuation is also unattractive due to losses and no dividend, while recent financing and early clinical progress provide only a modest offset.
To see Spark’s full report on APRE stock, click here.
More about Aprea Therapeutics
Aprea Therapeutics is a precision oncology company focused on synthetic lethality and DNA damage response (DDR) inhibition, developing highly targeted cancer therapies designed to destroy tumor cells by blocking their repair pathways while sparing healthy tissue. Its pipeline centers on next-generation DDR agents, including an ATR inhibitor (ATRN-119) and a WEE1 inhibitor (APR-1051), aimed at biomarker-selected patient populations within the large and growing oncology market.
Average Trading Volume: 98,377
Technical Sentiment Signal: Sell
Current Market Cap: $6.29M
Learn more about APRE stock on TipRanks’ Stock Analysis page.